Literature DB >> 27233470

Functional Analysis of Missense Variants in the Putative Breast Cancer Susceptibility Gene XRCC2.

Florentine S Hilbers1, Martijn S Luijsterburg1, Wouter W Wiegant1, Caro M Meijers1, Moritz Völker-Albert1, Rick A Boonen1, Christi J van Asperen2, Peter Devilee1,3, Haico van Attikum1.   

Abstract

XRCC2 genetic variants have been associated with breast cancer susceptibility. However, association studies have been complicated because XRCC2 variants are extremely rare and consist mainly of amino acid substitutions whose grouping is sensitive to misclassification by the predictive algorithms. We therefore functionally characterized variants in XRCC2 by testing their ability to restore XRCC2-DNA repair deficient phenotypes using a cDNA-based complementation approach. While the protein-truncating variants p.Leu117fs, p.Arg215*, and p.Cys217* were unable to restore XRCC2 deficiency, 19 out of 23 missense variants showed no or just a minor (<25%) reduction in XRCC2 function. The remaining four (p.Cys120Tyr, p.Arg91Trp, p.Leu133Pro, and p.Ile95Leu) had a moderate effect. Overall, measured functional effects correlated poorly with those predicted by in silico analysis. After regrouping variants from published case-control studies based on the functional effect found in this study and reanalysis of the prevalence data, there was no longer evidence for an association with breast cancer. This suggests that if breast cancer susceptibility alleles of XRCC2 exist, they are likely restricted to protein-truncating variants and a minority of missense changes. Our study emphasizes the use of functional analyses of missense variants to support variant classification in association studies.
© 2016 WILEY PERIODICALS, INC.

Entities:  

Keywords:  XRCC2; breast cancer; cancer susceptibility; functional analysis; homologous recombination

Mesh:

Substances:

Year:  2016        PMID: 27233470     DOI: 10.1002/humu.23019

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  8 in total

1.  RAD51 paralogs promote genomic integrity and chemoresistance in cancer by facilitating homologous recombination.

Authors:  Janelle Louise Harris; Andrea Rabellino; Kum Kum Khanna
Journal:  Ann Transl Med       Date:  2018-12

2.  Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.

Authors:  Lisa Golmard; Laurent Castéra; Sophie Krieger; Virginie Moncoutier; Khadija Abidallah; Henrique Tenreiro; Anthony Laugé; Julien Tarabeux; Gael A Millot; André Nicolas; Marick Laé; Caroline Abadie; Pascaline Berthet; Florence Polycarpe; Thierry Frébourg; Camille Elan; Antoine de Pauw; Marion Gauthier-Villars; Bruno Buecher; Marc-Henri Stern; Dominique Stoppa-Lyonnet; Dominique Vaur; Claude Houdayer
Journal:  Eur J Hum Genet       Date:  2017-11-08       Impact factor: 4.246

3.  Genetic determinants of sporadic breast cancer in Sri Lankan women.

Authors:  Nirmala Dushyanthi Sirisena; Adebowale Adeyemo; Anchala I Kuruppu; Nilaksha Neththikumara; Nilakshi Samaranayake; Vajira H W Dissanayake
Journal:  BMC Cancer       Date:  2018-02-13       Impact factor: 4.430

4.  Evaluation of X-Ray Repair Cross-Complementing Family Members as Potential Biomarkers for Predicting Progression and Prognosis in Hepatocellular Carcinoma.

Authors:  Jie Mei; Huiyu Wang; Runjie Wang; Jiadong Pan; Chaoying Liu; Juanying Xu
Journal:  Biomed Res Int       Date:  2020-03-17       Impact factor: 3.411

5.  Inherited variants in XRCC2 and the risk of breast cancer.

Authors:  Wojciech Kluźniak; Dominika Wokołorczyk; Bogna Rusak; Tomasz Huzarski; Jacek Gronwald; Klaudia Stempa; Helena Rudnicka; Aniruddh Kashyap; Tadeusz Dębniak; Anna Jakubowska; Marcin Lener; Marek Szwiec; Joanna Tomiczek-Szwiec; Joanna Jarkiewicz-Tretyn; Magdalena Cechowska; Paweł Domagała; Agata Szymiczek; Maryam Bagherzadeh; Jan Lubiński; Steven A Narod; Mohammad R Akbari; Cezary Cybulski
Journal:  Breast Cancer Res Treat       Date:  2019-08-28       Impact factor: 4.872

Review 6.  Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer.

Authors:  Sarah J Taylor; Mark J Arends; Simon P Langdon
Journal:  Explor Target Antitumor Ther       Date:  2020-02-29

7.  Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients.

Authors:  Zhendong Liu; Wang Zhang; Xingbo Cheng; Hongbo Wang; Lu Bian; Jialin Wang; Zhibin Han; Yanbiao Wang; Xiaoyu Lian; Binfeng Liu; Zhishuai Ren; Bo Zhang; Zhenfeng Jiang; Zhiguo Lin; Yanzheng Gao
Journal:  Mol Med       Date:  2021-05-29       Impact factor: 6.354

8.  Regulation and pharmacological targeting of RAD51 in cancer.

Authors:  McKenzie K Grundy; Ronald J Buckanovich; Kara A Bernstein
Journal:  NAR Cancer       Date:  2020-09-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.